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A B S T R A C T
Phenytoin (5,5-diphenylhydantoin; DPH) induces expression of cytochromes P450 (CYPs). In-
teractions between DPH and tacrolimus suggested that the persistence of CYP induction
after discontinuation of DPH is dependent on the history of administration and dosing period
of DPH. However, the relationship between the duration of DPH administration and expres-
sion of CYPs in the liver and small intestine of rats is not known. Alterations in levels of
P-glycoprotein (P-gp; MDR1; ABCB1) as well as CYPs cause drug interactions in the small
intestine.We examined the effects of the duration of DPH administration on expression of
CYPs and P-gp in the liver and small intestine of rats. Rats were treated with DPH (100 mg/kg,
peroral (p.o.) twice a day (b.d.)) for 2, 4, 8, and 16 d. mRNA levels of CYPs and P-gp were ex-
amined using the total RNA extracted from the liver and duodenum 2 h and 24 h after the
final administration of DPH. CYP3A activities were determined using microsomes. DPH ad-
ministration for 2 d and 4 dmarkedly increasedmRNA levels of CYPs such as CYP3A1, CYP3A2,
CYP2B1, and CYP2B2 in the liver. A relatively long duration of DPH administration (8 d and
16 d) resulted in abolition of the induction of hepatic CYP but increased CYP3A activities
were maintained. These results suggest that the duration of DPH administration could be
an important determinant of hepatic CYP induction.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Cytochromes P450 (CYPs) belong to a superfamily of proteins
containing a heme cofactor. CYPs are expressed abundantly in
the liver and small intestine. CYPs are involved in themetabolism
of various endogenous and xenobiotic substrates. CYP inhibi-
tion and induction by xenobiotics are the causes of drug–drug
interactions and can result in adverse effects. It is known that
carbamazepine [1,2], phenobarbital [3–5], and phenytoin (5,5-
diphenylhydantoin; DPH) [6,7] are potent inducers of CYPs. DPH
also shows competitive inhibition for the hydroxylation of
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tolbutamide [8]. CYP3A4 in humans as well as CYP3A1 and
CYP3A2 in rats accounts for ≤30% of hepatic CYPs [9]. CYP3A
is very important in hepatic drug metabolism because CYP3A4
participates in themetabolism of ≈50% ofmarketed drugs [10,11].
Intestinal CYPs are involved in first-pass metabolism in addi-
tion to hepatic CYPs. The major intestinal isoforms of CYP3A
in rats are CYP3A9, CYP3A18, and CYP3A62 [12].
DPH is an anticonvulsant agent. Interactions between
DPH and tacrolimus have been reported [13]. Wada et al.
demonstrated that the persistence of CYP induction after
discontinuation of DPH was dependent on the history of ad-
ministration and dosing period of DPH [14]. Patients treated
consecutively with DPH display sustained interactions between
DPH and tacrolimus. However, the relationship between the du-
ration of DPH administration and CYP expression in the liver
and small intestine of rats is not known.
In addition to themetabolism of drugs by CYP3A in the small
intestine, drugs are subject to active efflux from cells by ad-
enosine triphosphate-binding cassette transporters such as
P-glycoprotein (P-gp; MDR1; ABCB1). Substrates for CYP3A and
P-gp overlap [15], showing a concerted barrier function for drug
absorption. Identification of changes in the expression and func-
tion of P-gp during drug therapy is important because P-gp is
the cause of drug interactions in the small intestine [16,17].
Therefore, we examined the effects of the duration of DPH ad-
ministration on P-gp expression in the small intestine.
Expression of CYPs and P-gp are regulated on the tran-
scription level by nuclear receptors such as the pregnane X
receptor (PXR) and constitutive androstane receptor (CAR)
[18–20].We also determined the effects of the duration of DPH
administration on expression of PXR and CAR.
2. Material and methods
2.1. Ethical approval of the study protocol
The study protocol was approved by the Committee for the Care
and Use of Laboratory Animals of the Faculty of Pharmacy of
Kinki University (Osaka, Japan).
2.2. Compounds and reagents
DPH was purchased from Sigma-Aldrich (Saint Louis, MO, USA).
TRIzol and a Bicinchoninic Acid (BCA) Protein Assay kit were
obtained from Life Technologies (Carlsbad, CA, USA) and Pierce
Biotechnology (Rockford, IL, USA), respectively. A P450-Glo
CYP3A4 Assay kit and a regeneration system for the reduced
form of nicotinamide adenine dinucleotide phosphate (NADPH)
were purchased from Promega (Madison, WI, USA). All other
chemicals and solvents were of the best purity available.
2.3. Animals and treatments
Six-week-old female Sprague–Dawley rats were purchased from
Japan SLC (Shizuoka, Japan). Animals were housed in a
temperature-controlled roomwith free access to standard labo-
ratory chow (MF diet; Oriental Yeast, Tokyo, Japan) and water.
Rats were treated with DPH (100 mg/kg, peroral (p.o.) twice a
day (b.d.)) for 2, 4, 8, and 16 d [21]. At 2 h and 24 h after the final
administration of DPH, animals were anesthetized with diethyl
ether. Then, the liver and the proximal 2–3 cm of the duode-
num were perfused with ice-cold physiologic (0.9%) saline and
removed. After flash freezing in liquid nitrogen, each sample
was preserved at −80 °C until used for RNA extraction and mi-
crosome preparation.
2.4. Determination of mRNA levels by real-time reverse
transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from samples of liver tissue and small
intestine tissue using TRIzol. mRNA expression was mea-
sured using RT-PCR, as described previously [22,23].
Oligonucleotide sequences for each mRNA target are shown
in Table 1. Data were analyzed using ABI Prism 7000 SDS (Life
Technologies) using the multiplex comparative method.
2.5. Preparation of hepatic microsomes
Liver samples were perfused with ice-cold 0.9% saline and
chopped into small pieces. A 25% (w/v) homogenate was made
in ice-cold 1.15% KCl solution using a Physcotron Homog-
enizer (Microtec, Chiba, Japan).The homogenate was centrifuged
at 12,000 × g for 20 min at 4 °C. The supernatant was centri-
fuged further at 105,000 × g for 60 min at 4 °C to obtain a
microsomal pellet. The latter was washed by resuspension in
3ml of 1.15% KCl.The suspension was centrifuged at 105,000 × g
for 30 min at 4 °C to obtain the final microsomal pellet, which
was resuspended in 1.5 ml of 1.15% KCl and stored at −80 °C
until use. Protein concentrations were determined using a BCA
Protein Assay kit.
Table 1 – Primer sequences used in PCR assays.
Gene Primer sequence (5′–3′)
CYP2B1 Forward: CAAGGAGAGTGGCATTGGAAAA
Reverse: AGGCCATTCCCAACAGAGAACTG
CYP2B2 Forward: CACAGGAAAGCGCATTTGTCT
Reverse: CCAAATGGCTTGACACAGAGAA
CYP2C12 Forward: AATTCCCCAACCCAGAGATGTT
Reverse: CCCACACATTTCCGTTTTCCT
CYP3A1 Forward: GCCTTTTTTTGGCACTGTGCT
Reverse: GCATTTGACCATCAAACAACCC
CYP3A2 Forward: TTTGCCATCATGGACACAGAGA
Reverse: GCTTTCCCCATAATCCCCACT
CYP3A9 Forward: CCATAACATCAATCCTTATATG
Reverse: GCACGCGTGATACAACACCACTATAGGC
CYP3A18 Forward: CCAATCTATCCTCTTCATCGGA
Reverse: CCCCGGGAAATTCACTGTCC
CYP3A62 Forward: GGAGATAAAGAGTCTCACC
Reverse: AGTTCTGCAGGACTCAGAC
Mdr1a Forward: CGTTGCCTACATCCAGGTTT
Reverse: TGGAGACGTCATCTGTGAGC
Mdr1b Forward: TCTGCCGAGCGTTACTAATCAA
Reverse: ATGCCCGTGTAATAGTAGGCGT
PXR Forward: GACGGCAGCATCTGGAACTAC
Reverse: TGATGACGCCCTTGAACATG
CAR Forward: CCACGGGCTATCATTTCCAT
Reverse: CCCAGCAAACGGACAGATG
18S ribosomal
RNA
Forward: CGCCGCTAGAGGTGAAATTC
Reverse: CCAGTCGGCATCGTTTATGG
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2.6. Measurement of CYP3A activity
CYP3A activity was determined using a P450-Glo CYP3A4 Assay
kit. CYP3A1 and CYP3A2 activities in rats and CYP3A4 activ-
ity in humans were measured according to manufacturer
instructions. Briefly, CYP3A reactions were carried out in a 96-
well plate (OptiPlate-96; PerkinElmer,Waltham, MA, USA). An
incubation mixture (total volume, 50 μl) was prepared that con-
tained 200 mM potassium phosphate buffer (pH 7.4), a NADPH
regeneration system, 20 μg rat liver microsomes, and 50 μM lu-
ciferin 6′ benzyl ether (luciferin-BE) as a substrate for CYP3A1
and CYP3A2. After preincubation for 10 min at 37 °C, the re-
action was initiated by addition of the NADPH regeneration
system and then incubated for 30 min at 37 °C with constant
shaking. The reconstituted luciferin detection reagent (50 μl)
was added to terminate the reaction and generate chemilu-
minescence. Luminescence was measured using FLUOstar
Optima (Moritex, Tokyo, Japan).
2.7. Statistical analyses
Statistical analyses were carried out using the Dunnett’s test
after analysis of variance.
3. Results and discussion
mRNA levels of CYP3A1 and CYP3A2 (Fig. 1a) and CYP3A ac-
tivities (Fig. 1b) in the liver after DPH administration were
determined. mRNA levels of CYP3A1 and CYP3A2 were in-
creased significantly 2 h and 24 h after the final administration
of DPH for 4 d. Longer duration of DPH administration (8 d and
16 d) resulted in recovery to the mRNA levels observed in con-
trols. CYP3A activities were increased significantly upon DPH
administration for 4, 8, and 16 d. At 24 h (but not 2 h) after the
final DPH administration for 2 d, significant increases in CYP3A
activities were observed. In preliminary study, the larger varia-
tions between individuals were observed in the longer term
after last administration of DPH (data not shown). These find-
ings suggested that 2 h after DPH administration for 2 d was
not a sufficient time for increases in levels of protein and ac-
tivity of CYP3A to be observed. Increased activities of CYP3A
showed persistence compared with those of CYP3A1 and
CYP3A2 mRNA after DPH administration.We primarily exam-
ined the mRNA levels and activities but not protein levels of
CYP3A. It has been reported that the expression of CYP1A,
CYP2B, CYP2C, and CYP3A mRNA were correlated with those
protein levels and metabolic activities in human liver [24,25]
and rat and human hepatocytes [26].
We examined the effects of duration of DPH administra-
tion on themRNA levels of CYP2B1,CYP2B2, and CYP2C12 (Fig. 2).
mRNA levels of CYP2B1 and CYP2B2 were increased signifi-
cantly at relatively short durations of DPH administration (2 d
and 4 d) and tended to return to control levels after DPH ad-
ministration for 8 d and 16 d. These results for CYP2B1 and
CYP2B2 were similar to those for CYP3A1 and CYP3A2. In
CYP2C12, slight changes in mRNA levels were observed upon
DPH administration. In control rats, CYP2C is highly ex-
pressed in the liver compared with CYP3A, which is different
Fig. 1 – Levels of CYP3A1 and CYP3A2 mRNA (a) and CYP3A activities (b) in the liver of rats treated with DPH (p.o., b.d.) for 2,
4, 8, and 16 d. At 2 h and 24 h after the final administration of DPH, the liver was excised. Data are the mean ± SEM
(n = 3–6). *p < 0.05, **p < 0.01, and ***p < 0.001 vs control, †p < 0.05 and ††p < 0.01 vs 2 h.
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to the situation in humans [27]. Reports of a marked induc-
tion of expression of CYP2C12 mRNA upon DPH administration
are lacking.
Hepatic mRNA levels of PXR and CARwere examined (Fig. 3).
Induction of expression of CYP mRNA by DPH is mediated pri-
marily through activation of CAR (but not PXR) in humans
[28–30]. At 2 h and 24 h after DPH administration for 2 d and
4 d, mRNA levels of PXR and CAR did not change, but mRNA
levels of CYP3A1, CYP3A2, CYP2B1, and CYP2B2were increased.
The ligand-activated transcriptional activities of PXR and CAR
could have increased without affecting alterations in the mRNA
levels of PXR and CAR. Further studies are needed to clarify the
precise effects of duration of DPH administration on the ac-
tivities of nuclear receptors. Interestingly, longer duration of
DPH administration (8 d and 16 d) resulted in the reduction of
expression of PXR and CARmRNA. Regulation of negative feed-
back for CYP3A1, CYP3A2, CYP2B1, and CYP2B2 may have
occurred. It has been reported that induction of CYPs is
limited by negative feedback [31,32]. Studies have shown that
DPH is metabolized predominantly by CYP2C9, CYP2C19, and
CYP3A4 [33–35]. In these CYP isoforms, hepatic CYP3A activi-
ties were increased in rats treated with DPH, suggesting that
DPH is eliminated from the body rapidly by repeat adminis-
tration of DPH.
To clarify the effects of duration of DPH administration on
expression of CYP and P-gp in the small intestine, mRNA levels
of CYP3A9, CYP3A18, CYP3A62, Mdr1a, and Mdr1b were
determined (Figs. 4 and 5). Slight effects of DPH administra-
tion on expression of CYP3A9, CYP3A18, and CYP3A62 were
observed compared with those on hepatic expression of CYP3A1,
CYP3A2, CYP2B1, and CYP2B2. CYP3A activities in the small in-
testine did not change upon DPH administration (data not
shown). Some drug interactions are mediated via P-gp in the
small intestine. mRNA levels of Mdr1a and Mdr1b in the small
intestine did not change upon DPH administration. In prelimi-
nary experiments, mRNA levels ofMdr1a andMdr1b in the liver
did not change (data not shown). The protein levels of P-gp
showed little correlation with the mRNA levels of Mdr1a and
Mdr1b [25]. Further studies are needed to clarify the effects of
DPH administration on P-gp activities.
4. Conclusion
DPH administration for 2 d and 4 d increased the mRNA levels
of hepatic CYPs such as CYP3A1, CYP3A2, CYP2B1, and CYP2B2
markedly. Relatively long duration of DPH administration (8 d
and 16 d) resulted in transcriptional negative feedback for
CYP3A1, CYP3A2, CYP2B1, and CYP2B2. However, the increased
activities of CYP3A were maintained.These results suggest that
the duration of DPH administration could be an important de-
terminant of CYP induction in the liver.
Fig. 2 – Levels of CYP2B1, CYP2B2, and CYP2C12 mRNA in the liver of rats treated with DPH (p.o., b.d.) for 2, 4, 8, and 16 d. At
2 h and 24 h after the final administration of DPH, the liver was excised. Data are the mean ± SEM (n = 3–4). *p < 0.05,
**p < 0.01, and ***p < 0.001 vs control.
Fig. 3 – Levels of PXR and CAR mRNA in the liver of rats treated with DPH (p.o., b.d.) for 2, 4, 8, and 16 d. At 2 h and 24 h after
the final administration of DPH, the liver was excised. Data are the mean ± SEM (n = 3–4). *p < 0.05, **p < 0.01, and
***p < 0.001 vs control.
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